Abstract
Overview
Introduction
An estimated 10 million people in the seven major markets have chronic HCV.
The current standard of care, pegylated interferon (Peg-IFN) plus ribavirin
(RBV), achieves long-term disease remission in approximately half of those
receiving treatment. More efficacious therapies are required to improve
treatment success in difficult-to-treat patients, in particular patients with
HCV genotype 1.
Scope
- Comprehensive overview of compounds in clinical development for HCV,
including interferons, small molecule antivirals and immunomodulators
- Revenue forecasts from 2006-2015 for key late-stage compounds and the HCV
market as a whole
- Appraisal of clinical trial design highlighting the rising complexity
associated with patient stratification and the trend towards multidrug therapy
- Expert opinion on late-stage drugs and their potential use, outlook on HCV
therapy evolution and analysis of prevailing unmet needs
Report Highlights
Concomitant with new drug launches from 2009 onwards, the HCV market is
estimated to double by 2010 and potentially quadruple by 2015. Growth will be
driven mainly by the rapid uptake of new drugs, the premium prices these will
be able to command and the expected increase in treatment rates.
Vertex' protease inhibitor VX-950 is the most promising antiviral in
late-stage development. The drug has demonstrated potent reduction of HCV RNA
following 14 or 28 days of therapy, prompting Vertex to assess the ability of
VX-950 to shorten treatment duration to 12 weeks. Blockbuster potential will
be conditional on favorable long-term toxicity.
HCV therapy is expected to evolve towards multidrug therapy consisting of
drugs with complementary mechanisms of action. In an increasingly crowded
market, attributes other than efficacy will gain importance, including
favorable tolerability, convenient dosing, and lack of drug-drug interactions,
particularly in HIV/HCV co-infection.
Reasons to Purchase
- Understand key growth drivers in the mid to long-term HCV market and
quantify the future size, scope and potential for new products
- Optimize R&D strategies and clinical trial design in line with evolving
treatment paradigms
- Benchmark the HCV pipeline against currently marketed products and market
needs
| 
View Cart
